Symbols / CRL Stock $169.80 +1.23% Charles River Laboratories International, Inc.

Healthcare • Diagnostics & Research • United States • NYQ
CRL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. James C. Foster J.D.
Exch · Country NYQ · United States
Market Cap 8.38B
Enterprise Value 10.82B
Income -144.34M
Sales 4.02B
FCF (ttm) 572.38M
Book/sh 64.30
Cash/sh 4.34
Employees 18,300
Insider 10d —
IPO Jun 23, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 13.76
PEG 0.12
P/S 2.09
P/B 2.64
P/C —
EV/EBITDA 12.35
EV/Sales 2.69
Quick Ratio 0.82
Current Ratio 1.29
Debt/Eq 81.95
LT Debt/Eq —
EPS (ttm) -2.90
EPS next Y 12.34
EPS Growth —
Revenue Growth -0.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-18
ROA 4.24%
ROE -4.23%
ROIC —
Gross Margin 34.98%
Oper. Margin 4.51%
Profit Margin -3.60%
Shs Outstand 49.34M
Shs Float 48.66M
Insider Own 0.85%
Instit Own 109.57%
Short Float 10.87%
Short Ratio 5.43
Short Interest 4.67M
52W High 228.88
vs 52W High -25.81%
52W Low 112.39
vs 52W Low 51.08%
Beta 1.62
Impl. Vol. 0.10%
Rel Volume 0.61
Avg Volume 1.01M
Volume 618.48K
Target (mean) $199.33
Tgt Median $200.00
Tgt Low $135.00
Tgt High $265.00
# Analysts 15
Recom Buy
Prev Close $167.74
Price $169.80
Change 1.23%
About

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$199.33
Mean price target
2. Current target
$169.80
Latest analyst target
3. DCF / Fair value
$208.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$169.80
Low
$135.00
High
$265.00
Mean
$199.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-14 main Barclays Overweight → Overweight $210
2026-04-13 main JP Morgan Neutral → Neutral $160
2026-02-25 main UBS Neutral → Neutral $175
2026-02-20 main TD Cowen Buy → Buy $235
2026-02-20 main Mizuho Neutral → Neutral $175
2026-02-19 main Barclays Overweight → Overweight $200
2026-02-19 main Evercore ISI Group Outperform → Outperform $200
2026-01-16 main Citigroup Buy → Buy $265
2026-01-13 main Evercore ISI Group Outperform → Outperform $260
2025-12-18 main Mizuho Neutral → Neutral $200
2025-12-15 main Barclays Overweight → Overweight $215
2025-12-15 main JP Morgan Neutral → Neutral $190
2025-11-11 main Morgan Stanley Equal-Weight → Equal-Weight $185
2025-11-10 main TD Cowen Buy → Buy $197
2025-11-06 main JP Morgan Neutral → Neutral $165
2025-11-06 main Barclays Overweight → Overweight $210
2025-11-06 up Baird Neutral → Outperform $199
2025-10-17 main Mizuho Neutral → Neutral $174
2025-10-06 up William Blair Market Perform → Outperform —
2025-10-03 main Evercore ISI Group Outperform → Outperform $200
News
RSS: Latest CRL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 GIRSHICK BIRGIT Chief Operating Officer — 328 $0.00 $0
2026-03-03 LAPLUME JOSEPH W Officer — 25 $174.54 $4,364
2026-03-02 FOSTER JAMES C Chief Executive Officer — 16,796 $178.61 $2,999,934
2026-01-30 GIRSHICK BIRGIT Chief Operating Officer — 9,500 $0.00 $0
2026-01-30 LAPLUME JOSEPH W Officer — 5,456 $0.00 $0
2026-01-30 PARISOTTO SHANNON M Officer — 4,236 $0.00 $0
2026-01-30 FOSTER JAMES C Chief Executive Officer — 39,031 $0.00 $0
2026-01-30 KNELL MICHAEL GUNNAR Chief Financial Officer — 1,668 $0.00 $0
2026-01-30 CREAMER VICTORIA L Officer — 5,006 $0.00 $0
2026-01-30 MINTZ MARK Chief Technology Officer — 1,797 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4,015.38
-0.85%
4,049.99
-1.92%
4,129.41
+3.86%
3,976.06
Operating Revenue
4,015.38
-0.85%
4,049.99
-1.92%
4,129.41
+3.86%
3,976.06
Cost Of Revenue
2,692.11
-0.96%
2,718.17
+3.48%
2,626.85
+4.51%
2,513.41
Reconciled Cost Of Revenue
2,467.86
-1.08%
2,494.90
+1.83%
2,450.17
+3.99%
2,356.12
Gross Profit
1,323.28
-0.64%
1,331.82
-11.36%
1,502.56
+2.73%
1,462.65
Operating Expense
922.14
+3.67%
889.47
+0.47%
885.29
+9.07%
811.68
Selling General And Administration
743.07
-1.06%
751.00
+0.42%
747.86
+12.44%
665.10
Total Expenses
3,614.25
+0.18%
3,607.64
+2.72%
3,512.15
+5.63%
3,325.09
Operating Income
401.14
-9.32%
442.35
-28.34%
617.26
-5.18%
650.98
Total Operating Income As Reported
25.16
-88.93%
227.35
-63.17%
617.26
-5.18%
650.98
EBITDA
410.84
-29.31%
581.14
-43.69%
1,032.12
+4.66%
986.15
Normalized EBITDA
786.81
-1.17%
796.14
-22.86%
1,032.12
+4.66%
986.15
Reconciled Depreciation
403.31
+11.49%
361.74
+15.16%
314.12
+3.37%
303.87
EBIT
7.53
-96.57%
219.40
-69.44%
717.99
+5.23%
682.28
Total Unusual Items
-375.97
-74.87%
-215.00
0.00
0.00
Total Unusual Items Excluding Goodwill
-375.97
-74.87%
-215.00
0.00
0.00
Special Income Charges
-375.97
-74.87%
-215.00
0.00
0.00
Impairment Of Capital Assets
375.97
+74.87%
215.00
0.00
0.00
Net Income
-144.34
-1501.75%
10.30
-97.83%
474.62
-2.39%
486.23
Pretax Income
-99.50
-206.86%
93.11
-83.98%
581.28
-6.69%
622.99
Net Non Operating Interest Income Expense
-102.09
+13.27%
-117.71
+10.49%
-131.51
-124.77%
-58.51
Interest Expense Non Operating
107.03
-15.25%
126.29
-7.62%
136.71
+130.57%
59.29
Net Interest Income
-102.09
+13.27%
-117.71
+10.49%
-131.51
-124.77%
-58.51
Interest Expense
107.03
-15.25%
126.29
-7.62%
136.71
+130.57%
59.29
Interest Income Non Operating
4.94
-42.39%
8.57
+65.03%
5.20
+566.15%
0.78
Interest Income
4.94
-42.39%
8.57
+65.03%
5.20
+566.15%
0.78
Other Income Expense
-398.55
-72.14%
-231.52
-342.34%
95.54
+213.00%
30.52
Other Non Operating Income Expenses
-22.58
-36.66%
-16.52
-117.29%
95.54
+213.00%
30.52
Tax Provision
42.66
-37.10%
67.82
-32.79%
100.91
-22.60%
130.38
Tax Rate For Calcs
0.00
+0.00%
0.00
+20.69%
0.00
-16.75%
0.00
Tax Effect Of Unusual Items
-78.95
-74.87%
-45.15
0.00
0.00
Net Income Including Noncontrolling Interests
-142.16
-662.11%
25.29
-94.74%
480.37
-2.48%
492.61
Net Income From Continuing Operation Net Minority Interest
-144.34
-1501.75%
10.30
-97.83%
474.62
-2.39%
486.23
Net Income From Continuing And Discontinued Operation
-144.34
-1501.75%
10.30
-97.83%
474.62
-2.39%
486.23
Net Income Continuous Operations
-142.16
-662.11%
25.29
-94.74%
480.37
-2.48%
492.61
Minority Interests
-2.17
+85.49%
-14.99
-160.95%
-5.75
+9.97%
-6.38
Normalized Income
152.68
-15.25%
180.15
-62.04%
474.62
-2.39%
486.23
Net Income Common Stockholders
-144.34
-1501.75%
10.30
-97.83%
474.62
-2.39%
486.23
Otherunder Preferred Stock Dividend
—
11.91
0.00
0.00
Diluted EPS
-2.91
-1555.00%
0.20
-97.83%
9.22
-2.74%
9.48
Basic EPS
-2.91
-1555.00%
0.20
-97.84%
9.27
-3.13%
9.57
Basic Average Shares
49.56
-3.53%
51.38
+0.30%
51.23
+0.82%
50.81
Diluted Average Shares
49.56
-4.00%
51.63
+0.34%
51.45
+0.29%
51.30
Diluted NI Availto Com Stockholders
-144.34
-1501.75%
10.30
-97.83%
474.62
-2.39%
486.23
Amortization
179.07
+29.32%
138.47
+0.75%
137.44
-6.23%
146.58
Amortization Of Intangibles Income Statement
179.07
+29.32%
138.47
+0.75%
137.44
-6.23%
146.58
Depreciation Amortization Depletion Income Statement
179.07
+29.32%
138.47
+0.75%
137.44
-6.23%
146.58
Depreciation And Amortization In Income Statement
179.07
+29.32%
138.47
+0.75%
137.44
-6.23%
146.58
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7,135.42
-5.22%
7,528.35
-8.13%
8,195.00
+7.79%
7,602.77
Current Assets
1,447.05
+3.13%
1,403.07
-12.78%
1,608.66
+11.79%
1,439.03
Cash Cash Equivalents And Short Term Investments
213.77
+9.85%
194.61
-29.69%
276.77
+18.32%
233.91
Cash And Cash Equivalents
213.77
+9.85%
194.61
-29.69%
276.77
+18.32%
233.91
Other Short Term Investments
—
—
—
—
Receivables
708.86
-1.67%
720.91
-7.62%
780.38
+3.72%
752.39
Accounts Receivable
518.73
-1.70%
527.71
-8.71%
578.08
+3.34%
559.41
Receivables Adjustments Allowances
-10.46
+42.83%
-18.30
+28.85%
-25.72
-128.07%
-11.28
Other Receivables
200.59
-5.16%
211.51
-7.24%
228.02
+11.63%
204.26
Inventory
299.10
+7.38%
278.54
-26.75%
380.26
+48.65%
255.81
Raw Materials
40.96
-4.84%
43.04
+1.76%
42.30
+8.75%
38.89
Work In Process
88.74
+71.37%
51.78
-13.30%
59.73
+23.49%
48.37
Finished Goods
169.40
-7.79%
183.72
-33.97%
278.24
+65.08%
168.55
Prepaid Assets
96.11
-6.88%
103.21
+17.45%
87.88
-1.64%
89.34
Restricted Cash
—
—
—
—
Other Current Assets
129.21
+22.13%
105.80
+26.89%
83.38
-22.50%
107.58
Total Non Current Assets
5,688.37
-7.13%
6,125.27
-7.00%
6,586.34
+6.86%
6,163.74
Net PPE
2,016.63
+0.01%
2,016.50
-0.85%
2,033.77
+9.49%
1,857.42
Gross PPE
3,554.34
+2.41%
3,470.61
+3.01%
3,369.08
+11.61%
3,018.55
Accumulated Depreciation
-1,537.70
-5.75%
-1,454.11
-8.90%
-1,335.31
-15.00%
-1,161.13
Properties
0.00
0.00
0.00
0.00
Land And Improvements
72.02
+0.40%
71.74
-9.82%
79.55
+36.70%
58.19
Buildings And Improvements
1,097.57
+2.61%
1,069.67
+1.49%
1,053.91
+9.36%
963.72
Machinery Furniture Equipment
1,413.49
+5.91%
1,334.67
+4.49%
1,277.31
+14.98%
1,110.89
Construction In Progress
171.60
+19.75%
143.31
-27.52%
197.72
-1.00%
199.71
Other Properties
361.42
-12.38%
412.49
+4.69%
394.03
+0.58%
391.76
Leases
438.23
-0.12%
438.75
+19.69%
366.56
+24.56%
294.27
Goodwill And Other Intangible Assets
3,104.25
-13.05%
3,570.01
-9.83%
3,959.10
+4.04%
3,805.18
Goodwill
2,764.25
-2.89%
2,846.61
-8.03%
3,095.05
+8.60%
2,849.90
Other Intangible Assets
340.00
-53.00%
723.40
-16.28%
864.05
-9.55%
955.27
Investments And Advances
206.97
-5.21%
218.35
-10.44%
243.81
-21.76%
311.60
Long Term Equity Investment
206.97
-5.21%
218.35
-10.44%
243.81
-21.76%
311.60
Non Current Accounts Receivable
—
—
—
—
Non Current Deferred Assets
67.33
+59.64%
42.18
+4.72%
40.28
-2.38%
41.26
Non Current Deferred Taxes Assets
67.33
+59.64%
42.18
+4.72%
40.28
-2.38%
41.26
Other Non Current Assets
293.19
+5.37%
278.23
-10.07%
309.38
+108.65%
148.28
Total Liabilities Net Minority Interest
3,924.23
-2.39%
4,020.27
-11.37%
4,536.00
-0.94%
4,579.27
Current Liabilities
1,120.32
+12.70%
994.10
-5.78%
1,055.08
-3.34%
1,091.59
Payables And Accrued Expenses
418.88
+12.50%
372.35
-6.15%
396.76
-6.79%
425.67
Payables
148.80
+6.03%
140.34
-16.93%
168.94
-17.96%
205.91
Accounts Payable
148.80
+6.03%
140.34
-16.93%
168.94
-17.96%
205.91
Current Accrued Expenses
270.08
+16.41%
232.01
+1.84%
227.82
+3.67%
219.76
Employee Benefits
—
—
—
—
Pensionand Other Post Retirement Benefit Plans Current
268.85
+49.85%
179.42
-15.88%
213.29
+8.23%
197.08
Total Tax Payable
—
—
—
—
Income Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
—
—
—
—
Current Deferred Liabilities
210.42
-15.26%
248.32
+2.69%
241.82
-8.49%
264.26
Current Deferred Revenue
210.42
-15.26%
248.32
+2.69%
241.82
-8.49%
264.26
Other Current Liabilities
222.16
+14.51%
194.01
-4.53%
203.21
-0.67%
204.57
Total Non Current Liabilities Net Minority Interest
2,803.91
-7.34%
3,026.17
-13.06%
3,480.92
-0.19%
3,487.68
Long Term Debt And Capital Lease Obligation
2,570.41
-5.64%
2,723.99
-11.17%
3,066.38
-1.00%
3,097.28
Long Term Debt
2,111.71
-4.64%
2,214.53
-16.34%
2,647.15
-2.23%
2,707.53
Long Term Capital Lease Obligation
458.70
-9.96%
509.46
+21.52%
419.23
+7.57%
389.75
Defined Pension Benefit
—
—
—
—
Non Current Pension And Other Postretirement Benefit Plans
—
—
—
—
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
95.20
-10.99%
106.96
-44.10%
191.35
-11.24%
215.58
Non Current Deferred Revenue
—
—
—
—
Non Current Deferred Taxes Liabilities
95.20
-10.99%
106.96
-44.10%
191.35
-11.24%
215.58
Other Non Current Liabilities
138.30
-29.15%
195.21
-12.54%
223.19
+27.67%
174.82
Stockholders Equity
3,164.63
-8.58%
3,461.50
-3.76%
3,596.88
+20.85%
2,976.29
Common Stock Equity
3,164.63
-8.58%
3,461.50
-3.76%
3,596.88
+20.85%
2,976.29
Capital Stock
0.49
-3.72%
0.51
-0.39%
0.51
+0.79%
0.51
Common Stock
0.49
-3.72%
0.51
-0.39%
0.51
+0.79%
0.51
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
49.22
-3.76%
51.14
-0.38%
51.34
+0.77%
50.94
Ordinary Shares Number
49.22
-3.76%
51.14
-0.38%
51.34
+0.77%
50.94
Treasury Shares Number
0.00
0.00
0.00
0.00
Additional Paid In Capital
1,947.30
-0.96%
1,966.24
+3.18%
1,905.58
+5.58%
1,804.94
Retained Earnings
1,388.62
-23.37%
1,812.10
-3.98%
1,887.22
+31.71%
1,432.90
Gains Losses Not Affecting Retained Earnings
-171.78
+45.87%
-317.35
-61.56%
-196.43
+25.04%
-262.06
Treasury Stock
0.00
0.00
0.00
0.00
Minority Interest
46.56
-0.02%
46.58
-25.02%
62.12
+31.57%
47.21
Other Equity Adjustments
-171.78
+45.87%
-317.35
-61.56%
-196.43
+25.04%
-262.06
Total Equity Gross Minority Interest
3,211.19
-8.46%
3,508.08
-4.12%
3,659.00
+21.02%
3,023.51
Total Capitalization
5,276.34
-7.04%
5,676.04
-9.10%
6,244.03
+9.86%
5,683.82
Working Capital
326.73
-20.11%
408.97
-26.12%
553.58
+59.33%
347.45
Invested Capital
5,276.34
-7.04%
5,676.04
-9.10%
6,244.03
+9.86%
5,683.82
Total Debt
2,570.41
-5.64%
2,723.99
-11.17%
3,066.38
-1.00%
3,097.28
Net Debt
1,897.94
-6.04%
2,019.93
-14.78%
2,370.38
-4.17%
2,473.62
Capital Lease Obligations
458.70
-9.96%
509.46
+21.52%
419.23
+7.57%
389.75
Net Tangible Assets
60.38
+155.65%
-108.50
+70.04%
-362.21
+56.30%
-828.88
Tangible Book Value
60.38
+155.65%
-108.50
+70.04%
-362.21
+56.30%
-828.88
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
737.65
+0.42%
734.58
+7.41%
683.90
+10.37%
619.64
Cash Flow From Continuing Operating Activities
737.65
+0.42%
734.58
+7.41%
683.90
+10.37%
619.64
Net Income From Continuing Operations
-142.16
-662.11%
25.29
-94.74%
480.37
-2.48%
492.61
Depreciation Amortization Depletion
403.31
+11.49%
361.74
+15.16%
314.12
+3.37%
303.87
Depreciation And Amortization
403.31
+11.49%
361.74
+15.16%
314.12
+3.37%
303.87
Other Non Cash Items
2.50
-92.47%
33.25
+2981.65%
1.08
-93.31%
16.12
Stock Based Compensation
71.08
+1.71%
69.89
-2.99%
72.05
-2.13%
73.62
Provisionand Write Offof Assets
6.06
-58.97%
14.77
-18.94%
18.23
+171.77%
6.71
Asset Impairment Charge
436.52
+39.10%
313.82
+551.06%
48.20
+308.86%
11.79
Deferred Tax
-75.29
-11.66%
-67.43
-32.46%
-50.90
-41.85%
-35.88
Deferred Income Tax
-75.29
-11.66%
-67.43
-32.46%
-50.90
-41.85%
-35.88
Operating Gains Losses
21.54
+58.71%
13.57
+114.01%
-96.87
-0.24%
-96.63
Change In Working Capital
14.08
+146.43%
-30.33
+70.38%
-102.38
+32.89%
-152.55
Change In Receivables
35.74
+65.36%
21.61
+164.64%
-33.43
+77.80%
-150.57
Change In Inventory
-48.78
-390.27%
16.80
+126.97%
-62.30
+20.66%
-78.52
Change In Payables And Accrued Expense
82.18
+296.24%
-41.88
-424.75%
-7.98
+82.19%
-44.82
Change In Accrued Expense
79.31
+387.31%
-27.60
-321.77%
12.45
+129.52%
-42.16
Change In Payable
2.87
+120.10%
-14.27
+30.14%
-20.43
-670.25%
-2.65
Change In Account Payable
2.87
+120.10%
-14.27
+30.14%
-20.43
-670.25%
-2.65
Change In Other Working Capital
-55.06
-104.90%
-26.87
-2112.73%
1.33
-98.90%
121.36
Investing Cash Flow
-209.32
+14.59%
-245.09
+56.48%
-563.15
+7.36%
-607.92
Cash Flow From Continuing Investing Activities
-209.32
+14.59%
-245.09
+56.48%
-563.15
+7.36%
-607.92
Capital Expenditure
-219.15
+5.93%
-232.97
+26.86%
-318.53
+1.91%
-324.73
Net Investment Purchase And Sale
-10.97
+1.92%
-11.19
+76.47%
-47.55
+69.07%
-153.72
Purchase Of Investment
-20.08
+62.03%
-52.88
+2.47%
-54.22
+65.75%
-158.27
Sale Of Investment
9.10
-78.17%
41.69
+525.27%
6.67
+46.56%
4.55
Net Business Purchase And Sale
17.44
+418.32%
-5.48
+97.19%
-194.78
-62.16%
-120.12
Purchase Of Business
0.00
+100.00%
-5.48
+97.19%
-194.78
+31.27%
-283.39
Gain Loss On Sale Of Business
-3.38
-612.29%
0.66
-31.43%
0.96
+100.78%
-123.41
Net Other Investing Changes
3.36
-26.05%
4.55
+298.30%
-2.29
+75.46%
-9.35
Financing Cash Flow
-536.73
+2.58%
-550.93
-544.20%
-85.52
-101.71%
-42.40
Cash Flow From Continuing Financing Activities
-536.73
+2.58%
-550.93
-544.20%
-85.52
-101.71%
-42.40
Net Issuance Payments Of Debt
-121.78
+70.45%
-412.19
-447.23%
-75.32
-480.53%
19.79
Issuance Of Debt
1,227.53
+13.49%
1,081.58
+39.32%
776.35
-73.70%
2,952.43
Repayment Of Debt
-1,349.32
+9.67%
-1,493.77
-75.39%
-851.68
+70.96%
-2,932.64
Long Term Debt Issuance
1,227.53
+13.49%
1,081.58
+39.32%
776.35
-73.70%
2,952.43
Long Term Debt Payments
-1,349.32
+9.67%
-1,493.77
-75.39%
-851.68
+70.96%
-2,932.64
Net Long Term Debt Issuance
-121.78
+70.45%
-412.19
-447.23%
-75.32
-480.53%
19.79
Net Common Stock Issuance
-360.67
-202.64%
-119.17
-393.38%
-24.16
+37.50%
-38.65
Common Stock Payments
-360.67
-202.64%
-119.17
-393.38%
-24.16
+37.50%
-38.65
Repurchase Of Capital Stock
-360.67
-202.64%
-119.17
-393.38%
-24.16
+37.50%
-38.65
Proceeds From Stock Option Exercised
0.71
-97.01%
23.88
-6.72%
25.60
+1.94%
25.11
Net Other Financing Charges
-54.98
-26.57%
-43.44
-273.21%
-11.64
+76.07%
-48.65
Changes In Cash
-8.40
+86.33%
-61.44
-274.43%
35.22
+214.81%
-30.68
Effect Of Exchange Rate Changes
18.83
+207.75%
-17.47
-317.23%
8.04
-68.55%
25.58
Beginning Cash Position
205.57
-27.74%
284.48
+17.94%
241.21
-2.07%
246.31
End Cash Position
216.00
+5.07%
205.57
-27.74%
284.48
+17.94%
241.21
Free Cash Flow
518.49
+3.37%
501.61
+37.29%
365.37
+23.89%
294.91
Interest Paid Supplemental Data
—
123.45
-6.55%
132.10
+31.11%
100.75
Income Tax Paid Supplemental Data
—
126.06
+39.49%
90.37
+19.06%
75.91
Earnings Losses From Equity Investments
24.91
+92.96%
12.91
+113.20%
-97.83
-465.37%
26.77
Sale Of Business
17.44
0.00
0.00
-100.00%
163.28
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category